Medication info
Olamax Tablets 20/5/5 mg (Olmesartan Medoxomil, Amlodipine, Rosuvastatin)

Olamax Tablets 20/5/5 mg (Olmesartan Medoxomil, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletAmlodipine Besylate›6.95mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Daewoong Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201901263 · Approved 2019.02.27 · Insurance code 641606750

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medication should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). This medication is intended for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the olmesartan medoxomil/amlodipine combination and rosuvastatin. For patients taking olmesartan medoxomil/amlodipine in combination with rosuvastatin, they may be switched to this medication (a combination product containing the same amounts of each active ingredient) for convenience. ◆ Olmesartan medoxomil/amlodipine combination Before starting this medication, it is recommended that the doses of the individual components (olmesartan medoxomil or amlodipine) be adjusted. However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medication may be considered. The maximum dose of this medication is 40/10 mg. The maximum blood-pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows (olmesartan medoxomil/amlodipine): - 20/5 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg or amlodipine 5 mg monotherapy. - 40/5 mg: For patients whose blood pressure is not adequately controlled with 20/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with 40/5 mg. ∘ Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective circulating blood volume: In patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medication must not be administered to patients with severe hepatic impairment. (See “Do not administer to the following patients” under Precautions for Use.) ∘ Older adults: In general, initiate treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbid conditions into consideration. In older adults, blood pressure should be monitored more closely and more frequently. ◆ Rosuvastatin ∘ Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose for adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg once daily. ∘ Older adults: No dose adjustment is necessary. ∘ Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20mg to patients with moderate renal impairment. ∘ Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. ∘ Ethnicity: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. ∘ Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin at a dose of 40 mg is contraindicated in some of these patients.

Ingredients

Manufacturer
Daewoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used for the treatment of essential hypertension in patients for whom blood pressure control is difficult with monotherapy using a combination of Olmesartan Medoxomil and Amlodipine. Additionally, Rosuvastatin assists in the management of various types of hyperlipidemia that cannot be controlled by diet and exercise alone, and is particularly used as an adjunct in patients with familial hypercholesterolemia or dysbetalipoproteinemia. This drug helps to lower LDL cholesterol levels in patients with high cholesterol, slows the progression of atherosclerosis, and reduces the risk of cardiovascular diseases. It reduces the risk of stroke, myocardial infarction, and complications after angioplasty in addition to controlling blood pressure and cholesterol. Overall, this medication is used to improve cardiovascular health by managing blood pressure and lipids simultaneously.

How to take

Adult dose

This medication should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). This medication is intended for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the olmesartan medoxomil/amlodipine combination and rosuvastatin. For patients taking olmesartan medoxomil/amlodipine in combination with rosuvastatin, they may be switched to this medication (a combination product containing the same amounts of each active ingredient) for convenience. ◆ Olmesartan medoxomil/amlodipine combination Before starting this medication, it is recommended that the doses of the individual components (olmesartan medoxomil or amlodipine) be adjusted. However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medication may be considered. The maximum dose of this medication is 40/10 mg. The maximum blood-pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows (olmesartan medoxomil/amlodipine): - 20/5 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg or amlodipine 5 mg monotherapy. - 40/5 mg: For patients whose blood pressure is not adequately controlled with 20/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with 40/5 mg. ∘ Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective circulating blood volume: In patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medication must not be administered to patients with severe hepatic impairment. (See “Do not administer to the following patients” under Precautions for Use.) ∘ Older adults: In general, initiate treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbid conditions into consideration. In older adults, blood pressure should be monitored more closely and more frequently. ◆ Rosuvastatin ∘ Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose for adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 mg once daily. ∘ Older adults: No dose adjustment is necessary. ∘ Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering rosuvastatin 20mg to patients with moderate renal impairment. ∘ Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. ∘ Ethnicity: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. ∘ Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin at a dose of 40 mg is contraindicated in some of these patients.

Precautions

This medication can cause serious injury or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be immediately discontinued upon confirmation of pregnancy. Patients with allergies to this drug's active ingredients or components, patients with certain liver or kidney diseases, pregnant or breastfeeding women, and those taking specific medications should not take this drug. Patients who are deficient in fluid or salt or have cardiovascular disease, liver impairment, or kidney impairment may experience hypotension or other side effects when taking this medication, so they should be monitored carefully. This drug can cause serious muscle-related side effects, such as myalgia, myopathy, and rarely muscle rupture; therefore, any signs of muscle pain or weakness should prompt immediate consultation with a healthcare provider. It may affect liver function, so if liver function test results show abnormalities, dosages might need to be adjusted or discontinued. During the course of taking this medication, it is crucial to regularly monitor blood pressure, kidney function, liver function, and blood potassium levels to check for abnormalities. Taking it with certain foods, such as grapefruit juice, can enhance the drug's effects or increase the risk of side effects; caution is advised. Interactions may occur when taken in conjunction with certain drugs, so it is important to inform your doctor or pharmacist if you are taking other medications. This drug contains lactose, so patients with lactose intolerance or related genetic conditions should not take it. If unexpected symptoms or adverse reactions occur while taking this medication, alert healthcare personnel immediately to receive appropriate measures.

Side effects

Palpitations, abdominal pain, vomiting, weakness, peripheral edema, bacterial pneumonia, subarachnoid hemorrhage, increased ALT, increased AST, hypoglycemia, dizziness, headache, hematuria, allergic rhinitis, cough, wet cough, rash, arterial embolism, drug hypersensitivity, hyperkalemia, decreased libido, orthostatic hypotension, drowsiness, sensory disturbance, sensory reduction, syncope, vertigo, chest palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, indigestion, diarrhea, constipation, dry mouth, urticaria, muscle tension, limb pain, back pain, erectile dysfunction, edema, dependent edema, fatigue, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreased hemoglobin, decreased hematocrit, multiple organ dysfunction syndrome, viral pneumonia, benign neoplasm, malignant neoplasm, neoplasm of unspecified type, adrenal adenoma, discomfort in the oropharynx, weakness, angioedema, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, acute renal failure, elevated serum creatinine, hair loss, itching, urticaria, autoimmune hepatitis, hyperkalemia, flushing, fatigue, edema, chest palpitations, dizziness, headache, drowsiness, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, myalgia, myopathy, immune-mediated necrotizing myopathy, myalgia, headache, increased CK, constipation, increased AST, joint pain, numbness, sensory abnormalities, chest discomfort, nausea, abdominal pain, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, joint pain, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal liver failure, non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, back pain, bronchitis, increased creatine phosphokinase, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, cough, vomiting, chronic malabsorption syndrome, intestinal vascular edema, hair loss, itching, urticaria, angioedema, nausea, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, acute renal failure, elevated serum creatinine, hair loss, itching, urticaria, autoimmune hepatitis, hyperkalemia, flushing, fatigue, edema, chest palpitations, dizziness, headache, drowsiness, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, myalgia, myopathy, immune-mediated necrotizing myopathy, myalgia, headache, increased CK, constipation, increased AST, joint pain, numbness, sensory abnormalities, chest discomfort, nausea, abdominal pain, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It's recommended to keep it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow round film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.